Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma

Biochemical and Biophysical Research Communications

Volumn 457, Issue 3, 2015, Pages 461-466

  Li, Yixin ^a   Wang, Xiqian ^a   Bi, Shaojie ^a   Zhao, Kun ^a   Yu, Chao ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Axl; Chemosensitivity; Mer; Receptor tyrosine kinase; Targeted therapy

Indexed keywords

AXL RECEPTOR TYROSINE KINASE; CISPLATIN; FAK PROTEIN; GROWTH ARREST SPECIFIC PROTEIN 6; MER RECEPTOR TYROSINE KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VINCRISTINE; GROWTH ARREST-SPECIFIC PROTEIN 6; LIGAND; MERTK PROTEIN, HUMAN; ONCOPROTEIN; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; VINCRISTINE;

EID: 84922715769     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.01.017     Document Type: Article

References (23)

1. G.M. Brodeur, Neuroblastoma: biological insights into a clinical enigma, Nat. Rev. Cancer 3 (2003) 203-216.
2. V. Castel, E. Villamon, A. Canete, S. Navarro, A. Ruiz, C. Melero, A. Herrero, Y. Yanez, R. Noguera, Neuroblastoma in adolescents: genetic and clinical characterisation, Clin. Transl. Oncol. 12 (2010) 49-54.
3. J.M. Maris, M.D. Hogarty, R. Bagatell, S.L. Cohn, Neuroblastoma, Lancet 369 (2007) 2106-2120.
4. G.M. Brodeur, R.C. Seeger, M. Schwab, H.E. Varmus, J.M. Bishop, Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage, Science 224 (1984) 1121-1124.
5. V. van Limpt, A. Schramm, A. van Lakeman, P. Sluis, A. Chan, M. van Noesel, F. Baas, H. Caron, A. Eggert, R. Versteeg, The Phox2B homeobox gene is mutated in sporadic neuroblastomas, Oncogene 23 (2004) 928-e9288.
6. R.E. George, T. Sanda, M. Hanna, S. Frohling, W. Luther 2nd, J. Zhang, Y. Ahn, W. Zhou, W.B. London, P. McGrady, L. Xue, S. Zozulya, V.E. Gregor, T.R. Webb, N.S. Gray, D.G. Gilliland, L. Diller, H. Greulich, S.W. Morris, M. Meyerson, A.T. Look, Activating mutations in ALK provide a therapeutic target in neuroblastoma, Nature 455 (2008) 975-978.
7. J. Yu, C. Rupasinghe, J.L. Wilson, L. Taylor, N. Rahimi, D. Mierke, P. Polgar, Targeting receptor tyrosine kinases and their downstream signaling with cellpenetrating peptides in human pulmonary artery smooth muscle and endothelial cells, Chem. Biol. Drug Des. (2014), http://dx.doi.org/10.1111/cbdd.12446.
8. M. Hojjat-Farsangi, Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies, Int. J. Mol. Sci. 15 (2014) 13768-13801.
9. A.M. Pierce, A.K. Keating, TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system, Brain Res. 1542 (2014) 206-220.
10. W.I. Tsou, K.Q. Nguyen, D.A. Calarese, S.J. Garforth, A.L. Antes, S.V. Smirnov, S.C. Almo, R.B. Birge, S.V. Kotenko, Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation, J. Biol. Chem. 289 (2014) 25750-25763.
11. K.H. Knubel, B.M. Pernu, A. Sufit, S. Nelson, A.M. Pierce, A.K. Keating, MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme, Oncotarget 5 (2014) 1338-1351.
12. X. Wu, X. Liu, S. Koul, C.Y. Lee, Z. Zhang, B. Halmos, AXL kinase as a novel target for cancer therapy, Oncotarget 5 (2014) 9546-9563.
13. C.W. Wu, A.F. Li, C.W. Chi, C.H. Lai, C.L. Huang, S.S. Lo, W.Y. Lui, W.C. Lin, Clinical significance of AXL kinase family in gastric cancer, Anticancer Res. 22 (2002) 1071-1078.
14. K.K. Matthay, J.G. Villablanca, R.C. Seeger, D.O. Stram, R.E. Harris, N.K. Ramsay, P. Swift, H. Shimada, C.T. Black, G.M. Brodeur, R.B. Gerbing, C.P. Reynolds, Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group, N. Engl. J. Med. 341 (1999) 1165-1173.
15. C. Gjerdrum, C. Tiron, T. Hoiby, I. Stefansson, H. Haugen, T. Sandal, K. Collett, S. Li, E. McCormack, B.T. Gjertsen, D.R. Micklem, L.A. Akslen, C. Glackin, J.B. Lorens, Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 1124-1129.
16. T.M. D'Alfonso, J. Hannah, Z. Chen, Y. Liu, P. Zhou, S.J. Shin, Axl receptor tyrosine kinase expression in breast cancer, J. Clin. Pathol. 67 (2014) 690-696.
17. R.M. Linger, A.K. Keating, H.S. Earp, D.K. Graham, Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors, Expert Opin. Ther. Targets 14 (2010) 1073-1090.
18. A.B. Lee-Sherick, K.M. Eisenman, S. Sather, A. McGranahan, P.M. Armistead, C.S. McGary, S.A. Hunsucker, J. Schlegel, H. Martinson, C. Cannon, A.K. Keating, H.S. Earp, X. Liang, D. DeRyckere, D.K. Graham, Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia, Oncogene 32 (2013) 5359-5368.
19. W.P. Lee, Y. Wen, B. Varnum, M.C. Hung, Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis, Oncogene 21 (2002) 329-336.
20. J. Chen, K. Carey, P.J. Godowski, Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation, Oncogene 14 (1997) 2033-2039.
21. Y. Li, X. Ye, C. Tan, J.A. Hongo, J. Zha, J. Liu, D. Kallop, M.J. Ludlam, L. Pei, Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis, Oncogene 28 (2009) 3442-3455.
22. P.D. Dunne, D.G. McArt, J.K. Blayney, M. Kalimutho, S. Greer, T. Wang, S. Srivastava, C.W. Ong, K. Arthur, M. Loughrey, K. Redmond, D.B. Longley, M. Salto-Tellez, P.G. Johnston, S. Van Schaeybroeck, AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer, Clin. Cancer Res. 20 (2014) 164-175.
23. R.M. Linger, R.A. Cohen, C.T. Cummings, S. Sather, J. Migdall-Wilson, D.H. Middleton, X. Lu, A.E. Baron, W.A. Franklin, D.T. Merrick, P. Jedlicka, D. DeRyckere, L.E. Heasley, D.K. Graham, Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer, Oncogene 32 (2013) 3420-3431.